It is bad news for asthma sufferers, as a UK biotech has abandoned the development of its smart inhaler after finding that it was no better than placebo in a Phase III trial. Over 52 weeks of treatment, the company Vectura tested whether the inhaler
Updated: 11/26/2018 11:11A
Seattle Genetics Inc said it would halt a late-stage study of its drug to treat a type of leukemia in older patients following a higher rate of deaths in patients on the drug compared with those on a placebo. Shares of the U.S. drug developer fell as
Updated: 06/19/2017 12:35P